Literature DB >> 9677642

[Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide].

M Radal1, A P Jonville-Bera, C Van-Egroo, P Carré, E Lemarié, E Autret.   

Abstract

UNLABELLED: We report 3 cases of rash after the first dose of antituberculosis polytherapy, thus raising questions concerning the procedures to be followed. CASE REPORT: Three patients developed a pruritic rash 1 hour after the first dose of isoniazide, rifampicine, pyrazinamide and ethambutol given simultaneously. The eruption did not recur after readministration of isoniazide and rifampicine successively. Pyrazinamide, which was readministered last (at the full dose in one case and at progressive doses in the two others), induced a recurrence in two of them. Pyrazinamide was definitively withdrawn in one patient with recurrence and slower pyrazinamide readministration allowed continuation of treatment in the other two patients.
CONCLUSION: Since pyrazinamide appeared to be responsible for rash following the first administration of antituberculosis polytherapy, a protocol for readministration of the 4 drugs is suggested. If the responsibility of pyrazinamide is confirmed it should be readministered very slowly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9677642

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

1.  Pyrazinamide-induced phototoxicity: a case report and review of literature.

Authors:  Subodh K Katiyar; Shailesh Bihari; Shivesh Prakash
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

2.  Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.

Authors:  Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén
Journal:  World Allergy Organ J       Date:  2013-10-31       Impact factor: 4.084

3.  A case report. Rediscovering tuberculostatics drugs: skin rash and pyrazinamide.

Authors:  S Calpena Martínez; I Carrillo Acosta; B Álvarez Álvarez; M Górgolas Hernández-Mora
Journal:  Rev Esp Quimioter       Date:  2022-03-01       Impact factor: 2.515

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.